Publications by authors named "John M Vatkevitch"
Am J Clin Oncol
June 2021
Article Synopsis
- The study explored the safety and toxicity of combining nivolumab and low-dose ipilimumab in high-risk patients with completely resected melanoma.
- Out of 21 patients, 48% experienced grade 3 treatment-related toxicities, but there were no severe cases (grade 4 or 5), and 71% completed the full treatment.
- With a median follow-up of 41 months, the 2-year recurrence-free survival rate was 85.7% and overall survival rate was 90.5%, suggesting this treatment could be beneficial, warranting further research.
